Clinical ink, a global life science technology company, today announced that experienced healthcare industry veteran Dr. Jonathan Goldman MD has joined the company as Chief Executive Officer (CEO). Jonathan succeeds Ed Seguine who has led Clinical ink since nearly fourteen years ago.
Newsroom
Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease research to deploy remote technology that captures study participants’ symptoms at home and clinical sites in the United States and Europe.
Attributes 241% revenue growth to therapeutic expertise and technological innovation Horsham, Pennsylvania — Clinical ink, a global life science technology company, today …
A research study within the US Military Health System deploys Clinical ink’s platform among those with and without COVID-19 to understand long …
Will deliver competitive commercial impact via differentiated technological, scientific expertise and operational efficiencies September 19, 2022 — Today Clinical ink, a global …
Product enhancements ensure faster, more reliable, and higher quality data collection Horsham, Pa.; September 14 , 2022 — Today Clinical ink, a …
Chief Innovation Officer to Speak on Importance of Applying User Experience Design Practices at DPHARM tech showcase and Mobile Technology in Clinical …
Corporate LiveWire’s Innovation & Excellence Awards Honors Clinical ink and its Innovative Approach to Industry Challenges Horsham, Pa.; August 15, 2022 — …
